Q-omics provides the consensus-scored TEX29 profile across patient tissues and cancer cell-line models. TEX29 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TEX29 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, TEX29 RNA expression shows 14,586 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where TEX29 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TEX29 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TEX29 survival associations across molecular data types. TEX29 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TEX29 RNA expression–survival associations across cancer types. High TEX29 expression shows unfavorable associations in KIRC, LIHC, COAD, READ and KICH, but favorable associations in UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TEX29 RNA expression.
This table summarizes TEX29 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TEX29. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TEX29 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, COAD, BRCA and BLCA. The HNSC box plot shows higher TEX29 RNA expression in tumor versus normal tissue (log2 FC = +0.659, t-test p < 0.001).
This table shows molecular features associated with TEX29 in patient tissues and cancer cell lines. In patient samples, TEX29 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TEX29 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
